Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384803 | 0.86 | CYP11B2 (0.54) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL594413 | 0.86 | CYP11B2 (0.54) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL13006578 | 0.86 | CYP11B2 (0.54) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL17518822 | 0.83 | CYP11B2 (0.60) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL23374542 | 0.82 | CYP11B2 (0.50) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL29351735 | 0.81 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL23374726 | 0.81 | CYP11B2 (0.53) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL4397664 | 0.81 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL12030758 | 0.80 | CYP11B2 (0.51) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL24188522 | 0.80 | CYP11B2 (0.51) | CYP11B2CHRNB2CHRNA4CHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024081345-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024054469-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023239710-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-4163856-A | Azetidine compounds and process for production | PHILIP MORRIS INCORPORATED (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CYP11B2 192/4885CHRNB2 1591/4885CHRNA4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.